Tumor-Agnostic Therapies: Is The TAPUR Study Right For You?
For our Season 9 opening episode, we're learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the TAPUR Study. You may wonder, what is TAPUR and how does it relate to agnostic treatments? The pioneer behind the study, Dr. Schilsky, explains clinical trials for agnostic therapeutics, how you can join a TAPUR trial, and what to expect.
Tumor-Agnostic Therapies: Is This a Paradigm Shift in Cancer Care?
Do tumor-agnostic therapies represent a radical shift in oncology? Join us on this 1st part of a 2-part series as Dr. Joshua Drago of MSKCC answers this question and points out the advantages as well as the treatment limitations of agnostic therapeutics.
Report Back From ASCO 2024: What’s the Latest in HR+ MBC?
We are thrilled to present an audio version of SHARE Cancer Support’s webinar “Report Back from ASCO 2024: Latest Updates on HR+ Metastatic Breast Cancer (MBC)”.
This episode is an in-depth report from the ASCO 2024 Annual Meeting, featuring the latest advancements and research in HR+ MBC. Hear from Dr. Kevin Kalinsky as we dive into the findings from the DESTINY-Breast06 and postMONARCH trials, exploring their implications and potential impact on treatment strategies.
Your Guide to Bone Mets: The Basics
Today’s episode is the first in a three part series covering all things related to bone metastasis. In this episode, we discuss the basics with Dr. Azeez Farooki and Dr. Monica Fornier, both specialists in their fields at MSK, diving into the latest breakthroughs in bone disease and breast cancer research. Topics include theories on why breast cancer spreads to the bones, as well as new drug protocols shaping the future of bone metastasis research and treatment. We unlock the wisdom of these top experts as they bridge the gaps between advancing research and patient care in a thought provoking conversation.
Report Back from SABCS 2023: Spotlight on the Latest in MBC
Today we are bringing you a special episode that we created in partnership with SHARE Cancer Support. It’s an audio version of a live webinar that was done this past February called Report Back from San Antonio Breast Cancer Symposium 2023. SABCS is the world’s leading breast cancer research meeting where scientists, patient advocates, and others dedicated to working in the field of cancer gather. In this podcast, Dr. Timothy Pluard highlighted promising research, targeted therapy, the evolving treatment after CDK 4/6 inhibitors, liquid biopsy and more.
Understanding Progression: How to Identify & Treat ESR1 Mutations in HR+ MBC
Today we are bringing you a special podcast that we created in partnership with SHARE Cancer Support called Understanding Progression: How to Identify and Treat ESR1 Mutations in HR+ MBC. This episode was produced from a live webinar from this past October. There has not been a new endocrine treatment in decades and many of us find out the endocrine treatment no longer works for us because the cancer has mutated. Kate Vieira Pfitzer and Victoria Goldberg are excited to bring Dr. Virginia Kaklamani to you. You will hear her explain this common problem, how to test for it, the new treatment option that is now available as well as many of the ongoing clinical trials for HR+ MBC.
Tony Laudico: One Year Without Lisa
Meet Tony Laudico, husband of 27 years to our beloved Lisa. In this episode, you will hear a remarkable and at times, heart wrenching account of Tony’s struggle to comprehend a life without the partnership that had sustained and defined him for 30 years. He will talk about the anguish of loss, a nightmare of "death-duties", the true meaning of grief, and the solace of friendship. Although not always easy listening, this is an uplifting story and a testament to the power of love.
Living & Aging with MBC: Dr. Rachel Freedman & Patient Experiences
What is old? What do you call old? Seniors? Elderly? Geriatrics? Older Adults? We have strong opinions about these terms and being included in this group. In general, breast cancer is a disease of aging and more common in older patients. As our population ages, it is becoming increasingly more common, and yet older patients have worse survival from their breast cancers than their younger counterparts at every stage of diagnosis & every subtype. We will ask Dr. Rachel Freedman, medical oncologist from Dana Farber, to explain and discuss what it means to be living & aging with MBC, along with a very special group of women living with MBC.
Recent Advances, Controversies, and Emerging Trends in MBC
Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.
2022 in Review: Best in MBC with Dr. Erika Hamilton
Welcome to the first Road to A Cure episode of Season 6. Our guest is the incomparable Dr. Erika Hamilton, a breast oncologist and researcher who, as she says herself, doesn’t shy away from difficult questions. In this episode, we get a review—subtype by subtype—of the biggest news over the past 15 months. Of course, we also talk about what is on the horizon in MBC.
Meditation, Mindfulness, and MBC: Finding Your Inner Calm
Can mindfulness and meditation help many of us living with MBC tame anxiety, improve emotional balance, and experience more joy? Expert guests and our patient panel share how this ancient practice can make a daily difference. Bonus: our podcast includes a special guided meditation created with MBC patients in mind.
Laughter as Medicine
Is laughter good medicine? These breast cancer survivors/thrivers say: Yes!
ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.
Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?
MSK’s Dr. Shanu Modi, lead investigator on the DESTINY-Breast04 trial, talks with the Our MBC Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.
Season 5: Interviews, MBC101, Giveaways, and Much More…
The Our MBC Life senior producers and co-hosts, Victoria Goldberg and Natalia Green join Anne Woodward in a conversation about the upcoming season 5 of the podcast and some new things the team is doing and exciting details for very special giveaways for the Our MBC Life merchandise.
ER Progression and Resistance: Causes, Consequences, and Hope
Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.
Dr. Stephanie Graff: Understanding Progression
What does it mean when our cancer shows progression? And how do we know when that happens? The Our MBC Life team gets the lowdown from Dr. Stephanie L. Graff.
Dr. Lidia Schapira: Hey Doc, What Are You Telling Me?
What can we, as patients, do to strengthen our communication and relationships with our oncologists? This episode of Our MBC Life, the first in our MBC 101 series, includes perspectives, insights and suggestions from both sides of the critical doctor-patient relationship
Dr. Priya Kumthekar: Glimpses of Hope for Leptomeningeal Metastases
Co-hosts Victoria Goldberg and Dr. Paula Jayne sit down with neuro-oncologist Dr. Priya Kumthekar to talk about leptomeningeal metastases: what they are, how are they treated, and what research is upcoming, including a discussion on ANGled, the new Phase 3 trial for MBC patients newly diagnosed with leptomeningeal metastases.